menu Search
Trevia

Trevia

sitagliptin

Manufacturer:

Getz Pharma

Distributor:

Getz Pharma
Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing
Concise Prescribing Info
Contents
Sitagliptin
Indications/Uses
Adjunct to diet & exercise in patients w/ type 2 DM: As monotherapy; dual therapy, in combination w/ metformin HCl or a sulphonylurea or a PPARγ agonist (ie, thiazolidinediones); triple therapy, in combination w/ metformin HCl & a sulphonylurea or w/ metformin HCl & a PPARγ agonist (ie, thiazolidinediones); in combination w/ insulin.
Click to view Trevia detailed prescribing information
Dosage/Direction for Use
100 mg once daily as monotherapy or as combination therapy. Patient w/ moderate renal insufficiency 50 mg once daily, severe renal insufficiency or ESRD requiring hemodialysis or peritoneal dialysis 25 mg once daily.
Click to view Trevia detailed prescribing information
Overdosage
View Trevia overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Patients w/ type 1 diabetes or for treatment of diabetic ketoacidosis. Childn <18 yr.
Click to view Trevia detailed prescribing information
Special Precautions
Discontinue if pancreatitis is suspected. Hypoglycemia in combination w/ a sulfonylurea or insulin. Not recommended for use in pregnancy. Do not administer during nursing.
Click to view Trevia detailed prescribing information
Use In Pregnancy & Lactation
Click to view Trevia detailed prescribing information
Adverse Reactions
Headache, hypoglycemia, URTI, nasopharyngitis, constipation, pruritus, pain in extremities, hypersensitivity reactions including anaphylactic responses, ILD, vomiting, acute pancreatitis, fatal & non-fatal haemorrhagic, necrotizing pancreatitis, angioedema, rash, urticarial, cutaneous vasculitis, exfoliative skin conditions including SJS, bullous pemphigoid, arthralgia, myalgia, back pain, arthropathy, worsening renal function including acute renal failure (sometimes requiring dialysis).
Click to view Trevia detailed prescribing information
Drug Interactions
Small effect on plasma digoxin conc.
Click to view Trevia detailed prescribing information
Storage
View Trevia storage conditions for details to ensure optimal shelf-life.
Description
View Trevia description for details of the chemical structure and excipients (inactive components).
Action
View Trevia mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Regulatory Classification
Rx
Presentation/Packing
Form
Trevia FC tab 100 mg
Packing/Price
14's (P350/box)
Form
Trevia FC tab 50 mg
Packing/Price
14's (P350/box)